ANB033

ANB033 is a novel anti-CD122 antagonist that targets the shared beta subunit of the receptors for IL-15 and IL-2

Phase 1b cohort in celiac disease to initiate by Q4 2025
R&D IR event in Q4 2025

Anti-CD122 antagonist reduces pathogenic T cells and NK cells

CD122 is a shared beta subunit of the receptors for IL-15 and IL-2
CD122 antagonist mAb will potently inhibit IL-15 and IL-2 biology

Both IL-15 and IL-2 mediate:

  • Proliferation and survival of T cell subsets, particularly CD8+ TEMRA, and NK cells
  • Inflammatory cytokine secretion (IFNγ) during T cell activation

ANB033 reduces pathogenic T cells

  • Preferentially inhibits lower affinity dimeric IL-2 receptor complex

ANB033 has targeted reduction of CD122 expressing TRM cells

  • TRM cells require IL-15 for survival
  • May potentially drive durable response

Hare E, et al. FOCIS 2023. June 2023

ANB033 potently targets multiple pathogenic drivers of celiac disease

IL-15 signaling antagonism

  • Reduces tissue damage by IL-15-mediated accumulation and killing activity of CD122+ intra-epithelial lymphocytes (IEL)

IL-2 signaling antagonism

  • Modulates other specific immune pathways active during immune response to gluten in individuals with celiac disease, including upstream CD4 T cell-derived IFNγ, IL-2 and downstream B cell-mediated antibody responses

Further information on ANB033 MoA, preclinical data, Phase 1a data, and celiac study design to be disclosed at Q4 2025 R&D event